Citation Impact
Citing Papers
Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
2000 Standout
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
2000 Standout
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
2016 Standout
Facts and Controversies in Systemic Treatment of Metastatic Breast Cancer
2004
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
2009 Standout
Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
2011 Standout
Pegylated Liposomal Doxorubicin and Trastuzumab in HER-2 Overexpressing Metastatic Breast Cancer: A Multicenter Phase II Trial
2006
Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status.
2003
Overcoming Endocrine Therapy Resistance by Signal Transduction Inhibition
2004
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
Colorectal cancer
1999
Prevalence, risk factors and clinical implications of malnutrition in French Comprehensive Cancer Centres
2010 Standout
Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers.
1998
Molecular imaging in drug development
2008 Standout
Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist
1999 Standout
Bolus injection (2–4min) versus short-term (10–20min) infusion of 5-fluorouracil in patients with advanced colorectal cancer: a prospective randomised trial
1998
8-Year Follow-up of Randomized Trial: Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Patients with Peritoneal Carcinomatosis of Colorectal Cancer
2008 Standout
Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
2014 Standout
Perspectives on cancer therapy-induced mucosal injury
2004 Standout
Immunoreactive dUMP and TTP pools as an index of thymidylate synthase inhibition; effect of tomudex (ZD1694) and a nonpolyglutamated quinazoline antifolate (CB30900) in L1210 mouse leukaemia cells
1996
Aromatase Inhibitors in Breast Cancer
2003
A Review of Coumarin Derivatives in Pharmacotherapy of Breast Cancer
2008
An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectal cancer
1999
Aromatase, aromatase inhibitors, and breast cancer
2011
Fluorouracil in colorectal cancer--a tale of two drugs: implications for biochemical modulation.
1997
Aromatase inhibitors for breast cancer: lessons from the laboratory
2003
Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women.
1998
An Early Phase II Study of Oral S-1, a Newly Developed 5-Fluorouracil Derivative for Advanced and Recurrent Gastrointestinal Cancers
1999
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
2014 Standout
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
2004 Standout
AGREE II: advancing guideline development, reporting and evaluation in health care
2010 Standout
Mature results from three large controlled studies with raltitrexed ('Tomudex')
1998
Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancer
2011
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
Use of aromatase inhibitors in breast carcinoma.
1999
Chemotherapy and the war on cancer
2005 Standout
Coumarins: Old Compounds with Novel Promising Therapeutic Perspectives
2010 Standout
Male breast cancer
2006 Standout
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Analysis of anticancer drugs: A review
2011 Standout
Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma
2014 Standout
5-Substituted-1H-tetrazoles as carboxylic acid isosteres: medicinal chemistry and synthetic methods
2002 Standout
Quality of systematic reviews used in guidelines for oncology practice
2006
Oestrogen receptor downregulation: an opportunity for extending the window of endocrine therapy in advanced breast cancer
2003
Drug discovery from medicinal plants
2005 Standout
Sequence-dependent growth inhibition and DNA damage formation by the irinotecan–5-fluorouracil combination in human colon carcinoma cell lines
1999
5-Fluorouracil: mechanisms of action and clinical strategies
2003 Standout
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial
2000 Standout
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
2001 Standout
Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?
1998
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
2020 Standout
Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer.
1998
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
2009 Standout
Colorectal cancer chemotherapy
2003
New drugs in the treatment of colorectal carcinoma
1998
Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies
2006 Standout
Intrinsic and Acquired Resistance to Methotrexate in Acute Leukemia
1996
Pharmaceutical and therapeutic Potentials of essential oils and their individual volatile constituents: a review
2007 Standout
A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer
2003 Standout
S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial
2008 Standout
Final results of a randomised trial comparing ‘Tomudex’® (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer
1996
Chiral separation of raltitrexed by cyclodextrin-modified micellar electrokinetic chromatography
2008
Positron emission tomographic assessment of ?metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy
1999
Folate status and the safety profile of antifolates
2002
Azole fungicides affect mammalian steroidogenesis by inhibiting sterol 14 alpha-demethylase and aromatase.
2002 Standout
The Complex Role of Estrogens in Inflammation
2007 Standout
Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study
2009
EDC-2: The Endocrine Society's Second Scientific Statement on Endocrine-Disrupting Chemicals
2015 Standout
Carboxylic acid bioisosteres of γ-linked dipeptide analogues of the folate-based thymidylate synthase (TS) inhibitor, 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583)
1996
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
2011 Standout
Aromatase inhibitors as potential cancer chemopreventives.
1998
Interventions for preventing oral mucositis for patients with cancer receiving treatment
2011
Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore
2010 Standout
Basic Guide to the Mechanisms of Antiestrogen Action
1998
Aromatase Inhibitors in the Treatment of Breast Cancer
2005
Estrogen Receptor Null Mice: What Have We Learned and Where Will They Lead Us?
1999 Standout
Estrogen Suppression in Males: Metabolic Effects1
2000
Chromone: A Valid Scaffold in Medicinal Chemistry
2014 Standout
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
2004 Standout
Multitargeted Antifolate LY231514 as First-Line Chemotherapy for Patients With Advanced Non–Small-Cell Lung Cancer: A Phase II Study
1999
Hormones and Endocrine-Disrupting Chemicals: Low-Dose Effects and Nonmonotonic Dose Responses
2012 Standout
Interventions for treating oral mucositis for patients with cancer receiving treatment
2010
Breast Cancer and the Role of Cytokines in Regulating Estrogen Synthesis: An Emerging Hypothesis
1997
Design and Synthesis of Potent Non-Polyglutamatable Quinazoline Antifolate Thymidylate Synthase Inhibitors
1999
Trends in the Aggressiveness of Cancer Care Near the End of Life
2004 Standout
Steroidal and Nonsteroidal Sulfamates as Potent Inhibitors of Steroid Sulfatase
1998
Dendrimers Designed for Functions: From Physical, Photophysical, and Supramolecular Properties to Applications in Sensing, Catalysis, Molecular Electronics, Photonics, and Nanomedicine
2010 Standout
Photopharmacology: Beyond Proof of Principle
2014 StandoutNobel
Cytoreductive Surgery Combined With Perioperative Intraperitoneal Chemotherapy for the Management of Peritoneal Carcinomatosis From Colorectal Cancer: A Multi-Institutional Study
2004 Standout
Coumarins and Coumarin-Related Compounds in Pharmacotherapy of Cancer
2020 Standout
Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design
2011 Standout
Pretreatment of colon carcinoma cells with Tomudex enhances 5-fluorouracil cytotoxicity.
1998
Preventing and Managing Toxicities of High-Dose Methotrexate
2016 Standout
Works of M. Azab being referenced
A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer *
1996
‘Tomudex’ (ZD1694): Results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia
1995
Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.
1996
ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colorectal Study Group.
1996
ZD1694 (Tomudex): A new thymidylate synthase inhibitor with activity in colorectal cancer
1995